Explore the latest blogs and compelling articles about echocardiography, new research, and advances in technology.
Show all
Dr. Faizi Jamal shares how EchoGo® Heart Failure and EchoGo® Amyloidosis are integrated into clinical workflows to support early, more informed diagnosis.
Learn how Dr Schuster at University Cleveland Hospitals discusses his motives for using AI to detect HFpEF and the process of implementing AI into clinical practice.
Learn how AI-driven echocardiography is revolutionizing detection of cardiac amyloidosis. Discover the impact of faster, more accurate detection for improved patient care.
Explore challenges in cardiac amyloidosis diagnosis, from delays to misdiagnoses, and how AI could improve early detection and patient outcomes.
Ross Upton CEO and Founder of Ultromics explores the challenges and strategies for securing reimbursement for AI-driven echocardiography, essential for market success and patient care.
Uncover the causes, symptoms, and treatments for cardiac amyloidosis, offering hope and insights into managing this complex condition
"Learn how Ultromics secured four FDA clearances and two Breakthrough Designations in just four years. Explore our journey of innovation!"
SGLT2 inhibitors are emerging as a new and effective therapeutic option for patients with heart failure with preserved ejection fraction (HFpEF)
In honor of World Heart Day on September 29, we're diving into the world of cardiovascular diagnostics with top advances in echocardiography this last year.
Ultromics will share its groundbreaking AI research and innovation at the American Society of Echocardiography’s 2023 Scientific Sessions
Learn about what causes heart failure with preserved ejection fraction (HFpEF), including risk factors and clinical indicators.
Sign-up to hear about the latest news.
Sign up to newsletter
.jpg?noresize)
